QPPV.COM KNOWLEDGE ASSESSMENT

Besilesomab: Diagnostic Antibody, Radiopharmaceutical Use and Pharmacovigilance

Test your understanding of the concepts covered by Besilesomab: Diagnostic Antibody, Radiopharmaceutical Use and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A patient develops symptoms after receiving 99mTc-besilesomab. Which set of information would best support assessment of whether the event may be related to the product?
Question 2 of 10 A diagnostic report conflicts with another imaging modality, but the patient has no suspected clinical harm. How should the discrepancy be approached in aggregate review?
Question 3 of 10 A patient’s scan is negative, but a clinically significant event occurred after administration. Which approach is most appropriate?
Question 4 of 10 A report describes suspected osteomyelitis in an adult with diabetes and proposes imaging a diabetic-foot infection using Scintimun. What is the most appropriate regulatory interpretation?
Question 5 of 10 A suspected adverse-event case lacks the prepared 99mTc activity and the administration time. Why are these details important to follow up?
Question 6 of 10 A patient’s record contains no information about allergy to mouse antibodies or prior HAMA testing. What is the most appropriate next step when assessing suitability for administration?
Question 7 of 10 A safety reviewer is deciding whether to record a positive scan as evidence of bacterial infection. Which conclusion is most scientifically appropriate?
Question 8 of 10 Which description best captures the relationship between besilesomab and technetium-99m in Scintimun use?
Question 9 of 10 Why should the case record preserve the suspected condition that prompted imaging, the scan’s purpose, and subsequent diagnostic conclusions?
Question 10 of 10 A suspected loss of diagnostic performance is being investigated. Which group of factors is most relevant to consider?

Select an answer to continue.

QPPV.com